The United States will pay up to USD 2.1 billion for development including clinical trials, manufacturing, scale-up and delivery of its vaccine,” the companies said in a statement. Sanofi will get the bulk of the funds
The United States will pay up to USD 2.1 billion for development including clinical trials, manufacturing, scale-up and delivery of its vaccine,” the companies said in a statement. Sanofi will get the bulk of the funds